Drug
GTX-102
GTX-102 is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
2
50%
Ph phase_2
1
25%
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Completed(1)
Detailed Status
Active, not recruiting1
Completed1
Recruiting1
Enrolling by invitation1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 32 (50.0%)
Trials by Status
active_not_recruiting125%
completed125%
recruiting125%
enrolling_by_invitation125%
Recent Activity
2 active trials
Showing 4 of 4
active_not_recruitingphase_3
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
NCT06617429
enrolling_by_invitationphase_3
Long-term Extension of GTX-102 in Angelman Syndrome
NCT06415344
recruitingphase_2
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
NCT07157254
completedphase_1
A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome
NCT04259281
Clinical Trials (4)
Showing 4 of 4 trials
NCT06617429Phase 3
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
NCT06415344Phase 3
Long-term Extension of GTX-102 in Angelman Syndrome
NCT07157254Phase 2
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
NCT04259281Phase 1
A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4